南微医学公告，公司于2025年4月14日收到董事长隆晓辉先生《关于提议南微医学科技股份有限公司以 集中竞价交易方式回购公司社会公众股股份的函》。提议内容主要如下：回购股份的种类及方式为通过 上海证券交易所股票交易系统以集中竞价交易方式回购公司已发行的人民币普通股(A股)股票；回购股 份的用途为股权激励或员工持股计划；回购资金总额不低于人民币3000万元(含)，不超过人民币5000万 元(含)；回购股份的价格不超过董事会通过回购股份决议前30个交易日公司股票交易均价的150%；回购 资金来源为公司自有资金。 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-008 南微医学科技股份有限公司 关于收到《无效宣告请求审查决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 公司于2025年4月3日收到中华人民共和国国家知识产权局（以下简称"国家知 识产权局"）出具的《无效宣告请求审查决定书》（第586612号）。国家知识产权 局对北京中科盛康科技有限公司（以下简称"中科盛康"）提出的有关公司所持有 的"一种止血夹"发明专利无效宣告请求进行了审查。现将有关情况公告如下： 一、本次事项的基本情况 无效宣告请求审查结果：中华人民共和国国家知识产权局经审查决定，在 南微医学科技股份有限公司（以下简称"公司"）于2020年11月10日提交 的 权 利 要 求 1-8 基 础 上 维 持 公 司 的 " 一 种 止 血 夹 " （ 专 利 号 ： 201410222753.7）发明专利权有效。 公司所处的当事人地位：专利权人 是否会对公司损益产生负面影响：本次无效宣告事项不会对公司的日常生 产经营产生负 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 performance met expectations, with total revenue of 2.76 billion yuan (up 14.47% year-on-year) and net profit attributable to shareholders of 551.67 million yuan (up 13.53% year-on-year) [7] - The company is expanding its overseas presence through strategic acquisitions and partnerships, including the acquisition of a 51% stake in Creo Medical, which will enhance its sales network in Europe [7] - The establishment of a manufacturing center in Thailand is expected to boost production capabilities and support international market expansion [7] - Profit forecasts for 2024-2026 have been adjusted, with net profits projected at 5.52 billion yuan for 2024, 6.97 billion yuan for 2025, and 9.36 billion yuan for 2026, reflecting the company's leading position in overseas market expansion [7] Financial Summary - Total revenue for 2024 is projected at 2.76 billion yuan, with a year-on-year growth rate of 14.47% [1] - Net profit attributable to shareholders for 2024 is expected to be 551.67 million yuan, with a growth rate of 13.53% [1] - The company's earnings per share (EPS) is forecasted to be 2.94 yuan for 2024, with a price-to-earnings (P/E) ratio of 23.89 [1] - The company maintains a healthy financial position with a debt-to-asset ratio of 16.74% and a projected return on equity (ROE) of 13.76% for 2024 [6][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 performance met expectations, with total revenue of 2.76 billion yuan (up 14.47% year-on-year) and net profit attributable to shareholders of 551.67 million yuan (up 13.53% year-on-year) [7] - The company is expanding its overseas presence through strategic acquisitions and partnerships, including the acquisition of a 51% stake in Creo Medical, which will enhance its sales network in Europe [7] - The establishment of a manufacturing center in Thailand is expected to boost production capabilities and support international market expansion [7] - Profit forecasts for 2024-2026 have been adjusted, with net profits projected at 5.52 billion yuan for 2024, 6.97 billion yuan for 2025, and 9.36 billion yuan for 2026, reflecting the company's leading position in overseas market expansion [7] Financial Summary - Total revenue is projected to grow from 2.41 billion yuan in 2023 to 3.93 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 18.94% [8] - Net profit attributable to shareholders is expected to increase from 486 million yuan in 2023 to 936 million yuan in 2026, with a CAGR of approximately 34.30% [8] - The company's earnings per share (EPS) is forecasted to rise from 2.59 yuan in 2024 to 4.98 yuan in 2026 [8] - The price-to-earnings (P/E) ratio is projected to decrease from 27.12 in 2023 to 14.08 in 2026, indicating potential value appreciation [8]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [2][10]. Core Insights - The company is projected to achieve a revenue of 2.761 billion RMB in 2024, representing a year-on-year growth of 14%. The net profit attributable to shareholders is expected to be 552 million RMB, also up 14% year-on-year [1]. - The company is expanding its overseas market presence and enhancing its production capabilities with the establishment of a manufacturing center in Thailand, which will improve its risk resilience and production capacity for high-end medical devices [1]. - The acquisition of a 51% stake in Creo Medical S.L.U. will strengthen the company's position in the European market, particularly in the minimally invasive surgical equipment sector, and enhance its international sales network [2]. Summary by Sections Performance Overview - For 2024, the company anticipates a revenue of 2.761 billion RMB, a 14% increase from the previous year, and a net profit of 552 million RMB, also reflecting a 14% growth [1]. - In Q4 alone, the expected revenue is 748 million RMB, with a net profit of 101 million RMB, showing a 1% increase year-on-year [1]. Operational Analysis - The company is focusing on independent research and development, innovation in medical technology, and collaboration with academic institutions to deepen its domestic marketing and expand its overseas channels [1]. - The new manufacturing center in Thailand will be equipped with advanced technology and is expected to supply products primarily to the US, Europe, and Southeast Asia [1]. Mergers and Acquisitions - The company plans to acquire 51% of Creo Medical S.L.U. for up to 36.72 million euros, which will enhance its product offerings in Europe and complement its sales channels [2]. Profit Forecast and Valuation - The projected net profits for 2024, 2025, and 2026 are 552 million RMB, 696 million RMB, and 858 million RMB, respectively, with growth rates of 14%, 26%, and 23% [2]. - The current price-to-earnings (P/E) ratios are expected to be 23, 18, and 15 for the years 2024, 2025, and 2026 [2].

Financial Performance - The total operating revenue for 2024 reached RMB 2,760.51 million, an increase of 14.47% compared to the previous year[3] - The net profit attributable to the parent company was RMB 551.67 million, reflecting a growth of 13.53% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 542.87 million, up 17.21% from the previous year[3] - The basic earnings per share increased to RMB 2.94, a rise of 13.51% compared to the same period last year[3] - The total assets at the end of the reporting period were RMB 4,759.37 million, an increase of 8.35% from the beginning of the period[3] - The equity attributable to the parent company was RMB 3,831.03 million, which is a 6.07% increase from the beginning of the period[3] - The weighted average return on net assets improved to 14.94%, an increase of 0.69 percentage points year-on-year[3] Strategic Focus - The company continues to focus on independent research and development, medical engineering innovation, and industry-academia collaboration to enhance market presence[6] - The overseas channel coverage has further expanded, indicating a strategic move towards international market growth[6] Risk Awareness - The company emphasizes the importance of risk awareness as the financial data is preliminary and unaudited, urging investors to consider investment risks[7]

证券代码：688029 证券简称：南微医学 公告编号：2025-006 关于购买Creo Medical S.L.U.51%股权的进展公告 2025年2月15日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 一、交易概述 截至本公告披露日，双方《股权购买协议》约定的交易先决条件已满足，且 交易双方已按照《股权购买协议》的约定履行了股权交割程序,公司已取得了经 公证的CME股权证明文件，本次交易已完成，CME成为公司的控股子公司，纳入公 司合并报表范围。 特此公告。 南微医学科技股份有限公司 南微医学科技股份有限公司董事会 2024年9月18日，南微医学科技股份有限公司（以下简称"公司"）召开第 四届董事会第四次会议和第四届监事会第三次会议，分别审议通过了《购买Creo Medical S.L.U.51%股权的议案》，同意公司通过全资子公司Micro-Tech (NL) International B.V.使用自有资金不超过3,672万欧元购买Creo Medical Group plc持有的Creo Medical ...

关于 江苏新高的律师事务所 南微医学科技股份有限公司 2025 年第一次临时股东大会的 江苏新高的律师事务所 关于南微医学科技股份有限公司 2025 年第一次临时股东大会的见证法律意见书 苏高律股字[2025]第[0101]号 致：南微医学科技股份有限公司 见证法律意见书 地址：南京市秦淮区龙蟠中路 419 号人保（南京）金融大厦 A 座 9、10 楼 电话：（025）84715285 传真：（025）84703306 邮编：210001 江苏新高的律师事务所 关于南微医学科技股份有限公司 2025 年第一次临时股东大会的见证法律意见书 一、本次股东大会的召集、召开程序 （一）本次股东大会的召集 项、出席人员资格、投票方式等。 股东大会会议资料》。前述公告载明了本次股东大会召开的时间、地点、审议事 年 1 月 9 日在上交所网站发布《南微医学科技股份有限公司 2025 年第一次临时 学科技股份有限公司关于召开 2025 年第一次临时股东大会的通知》，并于 2025 年 12 月 25 日）在上海证券交易所（以下简称"上交所"）网站发布《南微医 本次股东大会由公司董事会召集，董事会已于会议召开 15 日以前（2 ...

南微医学科技股份有限公司 一、监事会会议召开情况 南微医学科技股份有限公司（以下简称"公司"）第四届监事会第六次会 议于 2025 年 1 月 16 日下午通过现场加通讯方式召开，会议通知及相关资料以 通讯方式于 2025 年 1 月 13 日送达全体监事。会议由监事会主席苏晶女士主持， 应到监事 3 名，实到监事 3 名，符合《中华人民共和国公司法》及《公司章程》 的有关规定。 二、监事会会议审议情况 本次监事会以记名投票表决方式审议通过以下议案： （一）审议通过《关于向控股子公司增资暨关联交易的议案》 监事会认为：公司向控股子公司康友医疗增资暨关联交易事项，符合康友 医疗实际经营发展需要，符合法律法规和规范性文件的要求，有利于康友医疗 提高资本规模、优化资本结构、补充营运资金，有利于推动康友医疗可持续发 展，提高其长期竞争力。同意本次向康友医疗增资暨关联交易事项。 证券代码：688029 证券简称：南微医学 公告编号：2025-005 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 表 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-003 南微医学科技股份有限公司 2025 年第一次临时股东大会决议公告 （二） 股东大会召开的地点：南京江北新区药谷大道 199 号 1 号楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 140 | | --- | --- | | 普通股股东人数 | 140 | | 2、出席会议的股东所持有的表决权数量 | 107,564,195 | | 普通股股东所持有表决权数量 | 107,564,195 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 57.5390 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 57.5390 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，董事长隆晓辉先生主持。大会采用现场投票和 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...